arrow
K

Kinuko Mitani

dokkyo medical university
H指数:47
被引数:8,264

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Addition of romiplostim to immunosuppressive therapy as first-line treatment for patients with aplastic anemia

将罗米司亭添加到免疫抑制疗法中,作为再生障碍性贫血患者的首选用药。

2025-08-060
OAAI
Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10)
LEUKEMIA
IF13.4
2024-12-230
OAAI
Efficacy and Safety of Eltrombopag Added to Rabbit Anti-Human Thymocyte Globulin plus Cyclosporine in Aplastic Anemia: Results from a Prospective Multicenter Phase II Study

Eltrombopag联合兔抗人胸腺细胞球蛋白与环孢素治疗再生障碍性贫血的疗效与安全性:一项前瞻性多中心II期研究的结果

BLOOD
IF23.1
2024-11-050
PRE
Long-term ef fi cacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study
2024-03-142
OA
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis

原发性血小板增多症后和真性红细胞增多症后骨髓纤维化的真实临床特征

2023-11-101
PRE
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model
2023-07-197
OAAI
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

慢性粒细胞白血病的急变转化中遗传异常的克隆进化和临床意义

2021-05-1450
OAAI
Clonal hematopoiesis in adult pure red cell aplasia
2021-01-2618
OAAI
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma
2020-04-044
PREAI
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
2018-07-0567
OAAI
Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: a multicenter retrospective study in Japan
2014-09-1240
OAAI